Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex, MolecularMD to Collaborate for CDx Development, Commercialization

NEW YORK (GenomeWeb) – Sysmex and MolecularMD have signed a non-exclusive collaboration agreement focused on the development and commercialization of companion diagnostics for precision medicine.

As part of the collaboration, the firms said they will integrate their capabilities and competencies to offer solutions to global pharmaceutical customers for CDx development and commercialization. The collaboration will address the time it takes to develop a diagnostic and will offer flexible structures for diagnostic test alignment with therapeutic drug approval.

According to Sysmex, the partnership will leverage the companies' US PMA, European CE, Japanese PMDA, and APAC regulatory experience in accelerating companion diagnostic and therapeutic drug commercialization.

The companies also noted that additional parties may have the opportunity to join the collaboration in the future.

In October, Sysmex received 510(k) clearance from the US Food and Drug Administration for its UD-130 Fully Automated Urine Particle Digital Imaging Device for locating, digitally storing, and displaying microscopic images from urine samples.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.